Trial Profile
A Dose Block-randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation, Phase I Clinical Study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Sep 2020
Price :
$35
*
At a glance
- Drugs KL 1333 (Primary)
- Indications Mitochondrial disorders
- Focus Adverse reactions; First in man
- Sponsors KT&G Life Sciences; Yungjin Pharm Co
- 16 Mar 2019 Results assessing tolerability of KL-1333 in healthy subjects, presented at the 120th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 21 May 2018 Results presented in a NeuroVive Pharmaceutical Media Release.
- 25 Apr 2018 Status changed from recruiting to completed.